Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

--- --- ------ --- Net loss applicable to common stockholders $(3,235) $(2,214) $(7,652) $(7,427) ======= ======= ======= ======= Net income (loss) per share applicable to common stockholders- basic and diluted: Loss from continuing operations $(0.04) $(0.03) $(0.11) $(0.10) Income from discontinued operations - - 0.01 - --- --- ---- --- Net loss applicable to Common stockholders $(0.04) $(0.03) $(0.10) $(0.10) ====== ====== ====== ====== Weighted-average number of common shares outstanding - basic and diluted: 77,582,829 75,842,169 77,256,895 74,307,956 


                                 Clarient, Inc.
          Reconciliation of Loss from Continuing Operations to "Adjusted
                                      EBITDA"

                                 Three months ended       Nine months ended
                                    September 30,            September 30,
                                  2009      2008(*)       2009        2008(*)
                                  ----       ------       ----        ------
    Loss from Continuing
     Operations, before income
     taxes                     $(3,235)    $(2,214)    $(4,862)      $(7,421)
    Income tax expense
     (benefit)                       -           -        (599)            6
    Interest Expense, net          144       2,399       4,056         5,747
    Depreciation &
     Amortization                1,039         961       2,820         2,815
    Stock Compensation Expense     501         241       1,640         1,424
                                  
'/>"/>
SOURCE  Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... 2013 •    First of its kind research ... ,     New facility will help solve crop stresses ... Syngenta unveiled its new crop research facility during ... Innovation Center. The first of its kind, $72 million ... agricultural climate and precisely measure plant inputs – the ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... Calif., March 10 MannKind,Corporation (Nasdaq: MNKD ... recent market events:, MannKind is absolutely committed ... Technosphere(R) Insulin. We use our small,patient-friendly Medtone(R) inhaler ... a way that much more closely matches the ...
... Judith K. Gwathmey VMD, Ph.D., FACC,FAHA has served ... Inc. for twelve years. Gwathmey, Inc. is an ... evaluation,of lead compounds prior to their conversion into ... a campaign with other members of the,quiet rural ...
... Anavex Life,Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced ... delay the growth of cancerous,tumors in patient-derived xenografts ... developed in ANAVEX labs using a sample,taken from ... cell sarcoma,is a rare type of melanoma (skin ...
Cached Biology Technology:MannKind Corporation Response to Recent Market Events 2MannKind Corporation Response to Recent Market Events 3MannKind Corporation Response to Recent Market Events 4MannKind Corporation Response to Recent Market Events 5MannKind Corporation Response to Recent Market Events 6Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 2Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 3Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 4Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 5Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 6
(Date:5/16/2013)... Fish fossils that are about 23 million years ... of the gobioid order, one of the most ... Researchers led by paleontologist Professor Bettina Reichenbacher from ... Department of Earth and Environmental Sciences at Ludwig-Maximilians-Universitaet ... comprehensive analysis of fish fossils which they assign ...
(Date:5/16/2013)... in Cameroon and the manager of San Diego Zoo ... prestigious Whitley award. The Whitley award is an ... because it celebrates the extraordinary achievements of some of ... Abwe was selected for the award due to his ... and its wildlife inhabitants., HRH The Princess Royal, the ...
(Date:5/15/2013)... moderating gout risk, new research reveals that vitamin C, ... (urate) levels to a clinically significant degree in patients ... combination with allopurinol, appears to have a weak effect ... to the results published in the American College of ... , Gout is an inflammatory arthritis that causes excruciating ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Vitamin C does not lower uric acid levels in gout patients 2
... Richard C. Willson has been named a 2010 Fellow ... (AAAS), which is the world,s largest general scientific society ... Willson is a professor of chemical and biomolecular engineering ... the AAAS for his "distinguished contributions to biomolecular recognition ...
... Conservation paleobiologists--scientists who use the fossil record to ... species to changes in their environment--are putting the ... the research in this emerging field provides examples ... environmental impacts, predict which species will be most ...
... Institute who have been studying prostate cancer cells for decades ... cancer progression. "This is the first demonstration of a ... a tumor to produce," said senior author Sal Pizzo, M.D., ... willing to bet there is also a connection in cancerous ...
Cached Biology News:University of Houston professor named 2010 AAAS Fellow 2Putting the dead to work 2Putting the dead to work 3Researchers learn why PSA levels reflect prostate cancer progression 2Researchers learn why PSA levels reflect prostate cancer progression 3
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Rabbit polyclonal to ADAMTS16 ( ... Antigen: Synthetic ... of human ADAMTS-16. Note: the amino ... Entrez GeneID: 170690 ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: